Look what I came across;
To: Benoit Desrochers (3579 )
From: gao seng Wednesday, Jul 14 1999 4:23PM ET
Reply # of 3745
Reuters: The company said it may try to challenge the mammography's dominance in the field.
Doing the math after reading the report, with a profit margin of say 25% would yield net income of 10 cents a share (assuming 100,000,000 shares) for a fair value of 2 dollars a share. (10 * 350,000 * 12 mos * .25) / 100,000,000 = .1
I have no idea of what the actual profit margin will be, but guess it would be much higher.
Breast cancer detection upstart begins laser trial
NEW YORK, July 13 (Reuters) - Imaging Diagnostic Systems Inc. (OTC BB:IMDS - news), an upstart in breast-cancer detection, said on Tuesday it began Phase II human trials of a laser technology it calls unique and hopes will one day become a clinical option.
Breast cancer detection is currently dominated by X-ray mammography, with MRI (magnetic resonance imaging) and ultrasound playing secondary roles in hospitals and clinics around the world.
The company hopes the trials on 400 women will show that its laser-detection system, called CTLM, or computer tomography laser mammography, is as effective as it is noninvasive.
A spokeswoman said that while current mammographic screenings require that heavy pressure be applied to the breast to insure X-rays penetrate tissues better, its CTLM requires only that a woman lie face down and ease her breast through a hole.
Under the table, a laser device spins around the breast and sends laser beams through it. Due to the different density of a tumor compared with surrounding tissue in the breast, the measuring equipment picks up changes in the beam's intensity.
These changes are recorded onto a CD-ROM, from which they are viewed as an image of consecutive cross-sections of the breast, not unlike an MRI.
Officials at the company stressed that due to the high speed of rotation, the laser does not leave any burns or bruises on the breast.
Indeed, the company had to prove this safety point in initial safety trials that enabled the Food and Drug Administration to allow the Phase II trials.
Phase II trials for medical devices usually lead to an FDA market clearance review. During such reviews, the agency decides whether to approve the technology for use as a diagnostics tool.
Such approval would mean that the laser technology could be used as a secondary detection method after traditional X-ray mammography.
If the Phase II approval is granted, Imaging Diagnostic Systems will be able to market its laser systems to hospitals and doctors. IDS hopes to sell 10 to 12 systems a month at $350,000 to $400,000.
After extensive use in hospitals and after more data are collected, the company said it may try to challenge the mammography's dominance in the field.
|
